Form 4: IN8BIO COO Acquires Shares Under 10b5-1 Plan

IN8BIO's Chief Operating Officer, Kate Rochlin, acquired 7,247 shares of common stock at $1.38 per share, adjusted for a recent 1-for-30 reverse stock split, under a pre-arranged 10b5-1 plan.

Summary

• Kate Rochlin, Chief Operating Officer of IN8BIO, INC., acquired 7,247 shares of common stock.
• The acquisition price was $1.38 per share.
• The transaction is scheduled for December 22, 2025.
• This transaction was made pursuant to a Rule 10b5-1(c) plan.
• Following this transaction, Ms. Rochlin will beneficially own 9,085 shares directly.
• The reported share numbers reflect an adjustment for a 1-for-30 reverse stock split effective June 3, 2025.

Sentiment

Score: 6

Explanation: The insider acquisition suggests confidence, but the context of a recent reverse stock split (often a negative signal) balances the sentiment. The 10b5-1 plan makes the transaction expected rather than a spontaneous vote of confidence.

Positives

• An insider (Chief Operating Officer) acquiring shares can be seen as a positive signal of confidence in the company's future prospects.
• The transaction is part of a pre-arranged 10b5-1 plan, indicating a structured approach to insider trading.

Negatives

• The acquisition price of $1.38 per share is relatively low, which might reflect the current market valuation of the stock.
• A reverse stock split (1-for-30) often indicates a company's stock price has fallen significantly, potentially raising concerns about its financial health or market perception.

Risks

• The reverse stock split, while a corporate action, can sometimes be a signal of underlying challenges or an attempt to meet listing requirements, which could be a risk factor for investors.

Future Outlook

The filing indicates a planned future acquisition of shares by a key executive on December 22, 2025, under a Rule 10b5-1 plan, suggesting a pre-determined strategy for insider stock transactions.

Industry Context

Insider buying, especially by a Chief Operating Officer, can be interpreted as a sign of confidence in the company's operational execution and future prospects within the biotechnology sector. However, the recent reverse stock split might suggest the company has faced challenges, which is not uncommon for early-stage biotech firms requiring capital and facing clinical trial risks.

Related Party Transactions

• Acquisition of 7,247 shares of common stock by Kate Rochlin, the Chief Operating Officer of IN8BIO, INC., from the issuer.

Stakeholder Impact

• Shareholders: The insider purchase could be viewed positively as a sign of management confidence, potentially influencing investor sentiment. The reverse stock split, however, has already impacted share structure and potentially liquidity.
• Management/Employees: The COO's investment aligns her interests further with shareholders.

Next Steps

• Execution of the stock acquisition by Kate Rochlin on December 22, 2025.

Key Dates

Recommendation

While insider buying by the COO suggests confidence, the context of a recent 1-for-30 reverse stock split often indicates underlying challenges or a need to maintain listing compliance, which can be a red flag. The transaction being part of a 10b5-1 plan makes it a pre-scheduled event rather than a spontaneous market-timing move. Investors should hold and monitor future developments, particularly around the company's operational performance and the impact of the reverse stock split, before making further investment decisions.

Keywords

IN8BIO, INAB, Form 4, Insider Trading, Stock Acquisition, Kate Rochlin, Chief Operating Officer, 10b5-1 Plan, Reverse Stock Split, Biotechnology, SEC Filing